Your browser doesn't support javascript.
loading
Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
Zhang, Yu-Chen; Wang, Jin-Ni; Ma, Shu-Yun; Cai, Jun; Su, Ning; Huang, Hui-Qiang; Li, Zhi-Ming; Xia, Zhong-Jun; Huang, He; Liu, Pan-Pan; Xia, Yi; Cai, Qing-Qing.
Afiliação
  • Zhang YC; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Wang JN; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Ma SY; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Cai J; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Su N; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Huang HQ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Li ZM; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Xia ZJ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Huang H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Liu PP; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Xia Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Cai QQ; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Br J Haematol ; 196(1): 127-135, 2022 01.
Article em En | MEDLINE | ID: mdl-34618912
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Morte Celular Programada 1 Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Morte Celular Programada 1 Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article